MedTrace Logo

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

NCT07315113 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-01-02

No results posted yet for this study

Summary

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Conditions

  • EGFR Mutation Positive Non-small Cell Lung Cancer
  • EGFR Mutated Non-small Cell Lung Cancer Patients

Interventions

DRUG

NXP900

NXP900 is an orally administered inhibitor of SRC family kinases (SFK)

DRUG

Osimertinib

Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor

Sponsors & Collaborators

  • Nuvectis Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Zofia Piotrowska, MD, MHS · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-18
Primary Completion
2026-12-31
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07315113 on ClinicalTrials.gov